RNA Analysis Market Expands With Growth in Molecular Biology Applications

The global RNA analysis market was estimated at USD 8.62 billion in 2024 and is projected to reach USD 23.65 billion by 2033, representing a compound annual growth rate (CAGR) of 12.55% from 2025-2033. Growth is being propelled by increasing demand for transcriptomic studies in precision medicine, advances in next-generation sequencing (NGS) technologies, and expanded applications of RNA biomarkers in disease diagnostics and drug discovery.

Key Market Trends & Insights and Market Size & Forecast

• The North American market held the largest share in 2024, capturing 43.49% of global revenue.
• By product category, kits & reagents dominated with a 59.18% share in 2024. On the technology side, NGS held the highest share in 2024, while in terms of application, infectious diseases and pathogenesis led for the same year.
• In terms of regional growth, the Asia Pacific region is expected to grow at the fastest CAGR of 13.41% between 2025 and 2033.
• The market size of USD 8.62 billion in 2024 is forecast to expand to USD 23.65 billion by 2033 under the 12.55% CAGR.

Technological advancement is a key driver: the rollout and adoption of high-throughput RNA sequencing (particularly NGS) has significantly enhanced the scope of transcriptomic profiling, enabling researchers to analyze gene expression patterns in depth across many samples and uncover novel RNA variants.

Drug development and vaccine research are also contributing heavily to market expansion. RNA-based therapeutics—such as mRNA vaccines and RNA interference treatments—are creating additional demand for RNA profiling and sequencing platforms.

The market exhibits characteristics of high innovation and moderate to high consolidation: many players are pursuing mergers and acquisitions to broaden their portfolios, acquire advanced sequencing technologies, and gain access to global distribution networks.

Regulatory frameworks also play a critical role: stringent guidelines around genetic and transcriptomic data, clinical trials and RNA-based therapeutics may impose delays, but they also enhance market confidence and support adoption of high-quality products.

From a segmentation perspective:

• The kits & reagents segment dominated in 2024 (59.18%).
• Services are projected to be the fastest-growing segment from 2025 to 2033, driven by increased R&D activity and outsourcing.
• Within technology, real-time PCR (qPCR) held the largest share in 2024 (43.34%) due to its widespread use, including in COVID-19 diagnostics.
• Sequencing is anticipated to grow fastest over the forecast period, supported by improvements in single-cell sequencing, decreasing costs and enhanced bioinformatics.
• Application-wise, infectious diseases & pathogenesis led in 2024 (17.90%).
• The epigenetics segment is expected to register strong growth ahead, based on increasing interest in gene regulation, disease prognosis and advanced molecular dynamics.
• As for end-use, government institutes & academic centres held 32.11% of revenue in 2024.
• Contract research organisations (CROs) are expected to grow at the fastest pace, thanks to strategic partnerships with sequencing technology providers.
• Regionally, North America’s dominance in 2024 (43.49%) is supported by strong research infrastructure, high biotech/pharma company density, and advanced sequencing adoption.
• Europe and Asia Pacific also show strong potential: Europe benefits from research activity and government initiatives; Asia Pacific is emerging as fastest-growing thanks to increasing biotech investment and lower-cost manufacturing.

Order a free sample PDF of the RNA Analysis Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insight

The RNA analysis industry is led by companies with broad product portfolios, strong R&D, global distribution and service capabilities. Several major firms have established substantial market share by offering advanced RNA sequencing systems, sample-preparation kits, high-throughput platforms and bioinformatics tools. These companies actively engage in innovation, collaboration and acquisition to maintain leadership.

Competitive pressures are intensifying as companies seek to combine technological innovation with increased accessibility and stronger data interpretation capabilities. The landscape is defined by strategic alliances, mergers and acquisitions, and the requirement to keep pace with evolving customer needs in precision medicine, drug discovery and RNA-based therapeutics.

Key Companies List

Major players in this market include:

• Agilent Technologies, Inc.
• Hoffmann-La Roche AG
• Illumina, Inc.
• QIAGEN
• Thermo Fisher Scientific, Inc.
• Eurofins Scientific
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Pacific Bioscience of California, Inc.
• Affymetrix, Inc.
• Danaher
• Promega

Conclusion

The RNA analysis market is clearly in a growth phase, driven by technological breakthroughs in sequencing, growing demands in precision medicine and drug development, and expanding applications across infectious disease, epigenetics and biomarker discovery. Companies that can deliver high-quality, high-throughput sequencing tools, robust bioinformatics, and flexible service models stand to gain significantly. Emerging regions, particularly in Asia Pacific, represent important future opportunities as research investment and infrastructure expand. Together, these trends suggest sustained market expansion and competitive evolution over the next decade.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.